Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,894 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Orozco Leal G, Armstrong N, Kernohan A, Ahmadu C, Coughlan D, McDermott K, Duffy S, O'Meara S, Robinson T, Vale L, Kleijnen J. Orozco Leal G, et al. Among authors: duffy s. Pharmacoeconomics. 2023 Jul;41(7):741-750. doi: 10.1007/s40273-023-01259-6. Epub 2023 Mar 23. Pharmacoeconomics. 2023. PMID: 36952138 Free PMC article. Review.
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE, Witlox W, Wolff R, Chalker A, Hiligsmann M, Wijnen B, Ahmadu C, Ryder S, Armstrong N, Duffy S, Syndikus I, Kleijnen J, Joore MA. Grimm SE, et al. Among authors: duffy s. Pharmacoeconomics. 2022 May;40(5):509-518. doi: 10.1007/s40273-021-01098-3. Epub 2021 Oct 19. Pharmacoeconomics. 2022. PMID: 34664200 Free PMC article. Review.
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Al Khayat MNMT, Armstrong N, Howick J, O'Meara S, Posadzki P, Ryder S, Ahmadu C, Konings SRA, Postma MJ, Duffy S, Wolff RF, van Asselt ADI. Al Khayat MNMT, et al. Among authors: duffy s. Pharmacoeconomics. 2023 Apr;41(4):353-361. doi: 10.1007/s40273-023-01247-w. Epub 2023 Feb 9. Pharmacoeconomics. 2023. PMID: 36757608 Free PMC article. Review.
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA. Ramaekers BLT, et al. Among authors: duffy s. Pharmacoeconomics. 2017 Feb;35(2):191-202. doi: 10.1007/s40273-016-0445-5. Pharmacoeconomics. 2017. PMID: 27566699 Free PMC article. Review.
Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".
Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA. Ramaekers BLT, et al. Among authors: duffy s. Pharmacoeconomics. 2017 Jun;35(6):665-667. doi: 10.1007/s40273-017-0507-3. Pharmacoeconomics. 2017. PMID: 28391508 No abstract available.
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT, Wolff R, van Giessen A, Pouwels X, Fayter D, Lang S, Armstrong N, Worthy G, Duffy S, Kleijnen J, Joore MA. Ramaekers BLT, et al. Among authors: duffy s. Pharmacoeconomics. 2018 Mar;36(3):285-288. doi: 10.1007/s40273-017-0591-4. Pharmacoeconomics. 2018. PMID: 29177842 Free PMC article. Review.
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV, Wolff R, Ramaekers BLT, Van Giessen A, Lang S, Ryder S, Worthy G, Duffy S, Armstrong N, Kleijnen J, Joore MA. Pouwels XGLV, et al. Among authors: duffy s. Pharmacoeconomics. 2018 May;36(5):533-543. doi: 10.1007/s40273-017-0607-0. Pharmacoeconomics. 2018. PMID: 29344794 Free PMC article. Review.
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Among authors: duffy s. Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4. Pharmacoeconomics. 2019. PMID: 30194622 Free PMC article. Review.
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox WJA, Grimm SE, Riemsma R, Armstrong N, Ryder S, Duffy S, Carrera VH, Posadzki P, Worthy G, Pouwels XGLV, Ramaekers BLT, Kleijnen J, Joore MA, van Asselt ADI. Witlox WJA, et al. Among authors: duffy s. Pharmacoeconomics. 2021 Feb;39(2):171-180. doi: 10.1007/s40273-020-00971-x. Epub 2020 Nov 4. Pharmacoeconomics. 2021. PMID: 33145711 Free PMC article. Review.
1,894 results